Email has been sent to with instructions on resetting your password.
Enroll in My Home to simplify finding a doctor and scheduling an appointment. Let's start!
By selecting "I Agree" or "Create Account" and clicking the box "I AGREE" below, you acknowledge and agree that you have read, understood and accepted the terms of service at the hyperlink below:
Legal and Privacy Notices
Awards and Recognitions
Community Health and Outreach
End of Life Option Act
Hospital Fast Facts
Media Policy and Guidelines
Mission, Vision and Values
Sponsorship Request Application
Dignity Health Heart and Vascular Institute is home to one of the largest and most recognized cardiovascular care teams in the state and includes the multidisciplinary TAVR team which has extensive experience, performing more than 400 cases. The TAVR physicians are trained to implant various FDA-approved devices. We offer additional technology through clinical research trials.
Aortic Stenosis is a progressive narrowing of the aortic valve resulting in reduction of blood flow out of the heart. TAVR is a minimally invasive procedure that treats aortic stenosis without requiring open heart surgery. The valve is placed on a catheter, inserted into an artery and advance to the narrowed aortic valve for deployment. TAVR is FDA-approved for patients considered intermediate to high-risk for surgical aortic valve replacement.
During TAVR, your surgeon will place the valve on a catheter which is inserted into an artery in the groin, rather than through an opening in the chest. The valve is threaded inside the faulty aortic valve and inflated. TAVR patients typically recover faster with less pain than patients undergoing open chest valve replacement.
In addition, Dignity Health Heart and Vascular Institute is a select site for TAVR clinical research, offering the newest valve designs, deployment methods, and access to a randomized trial for low risk patients who may not otherwise be eligible for TAVR.
Mercy General Hospital is now participating in a clinical trial to determine if TAVR provides the same or more benefits with less risk in healthier “low-risk” patients. For more information about this trial, call 916.453.4575.